TrialLung cancer (Amsterdam, Netherlands)2017

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

Helena A Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.